France Antibody Drug Conjugates Market Size & Outlook
Related Markets
France antibody drug conjugates market highlights
- The France antibody drug conjugates market generated a revenue of USD 167.6 million in 2021 and is expected to reach USD 811.8 million by 2030.
- The France market is expected to grow at a CAGR of 19.2% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 167.6 million |
| Market revenue in 2030 | USD 811.8 million |
| Growth rate | 19.2% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, France accounted for 2.9% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 67.9% in 2021. Horizon Databook has segmented the France antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
As per the International Agency for Research on Cancer, France with 467,995 new cases in 2020 was among the top 10 countries worldwide in terms of cancer incidence. The French Universal Health Coverage is mandatory for all citizens and provides full coverage for Long Tern Diseases (LTDs) such as cancer, with ADC drugs such as Roche’s Kadcyla already on the reimbursement list.
French pharmaceutical companies are actively investing in the development of ADC drugs. For instance, Sanofi’s SAR408701 is in phases 3 and 2 of clinical trials for non-small cell lung cancer & solid tumors, respectively.
High prevalence of cancer in France, excellent health care support for patients with LTDs, and ongoing R&D efforts from local pharmaceutical companies to develop new drugs are expected to propel the demand for ADC drugs market over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France antibody drug conjugates market size, by application, 2018-2030 (US$M)
France Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
